News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sagent Pharmaceuticals, Inc. Announces the Launch of Acetazolamide for Injection, USP



11/13/2012 8:14:19 AM

SCHAUMBURG, Ill., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Acetazolamide for Injection, USP, the generic form of the carbonic anhydrase inhibitor Diamox®, in a latex-free vial presentation. According to IMS data for the 12 months ending September 2012, the US market for Acetazolamide for Injection, USP approximated $9.5 million. As with all products in Sagent's portfolio, Acetazolamide features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES